Alkermes Investor Presentation Deck
March 2023, 32 slides
  1. Alkermes
  2. Related Decks
  3. Investor Presentation Decks
alkermes a clear investment thesis | Alkermes
| Alkermes
alkermes today sect see | Alkermes
post separation clear value propositions in and oncology arson alkermes company | Alkermes
clear priorities to unlock value in | Alkermes
drive launch of and commercial portfolio | Alkermes
and oral treatment option for adults with schizophrenia or bipolar i disorder | Alkermes
prescription growth trends reflect strong prescriber breadth and diverse source of business | Alkermes
indications represent a large opportunity | Alkermes
bipolar i disorder label relevant to real world patients | Alkermes
plans to launch direct to consumer advertising campaign focused on bipolar i disorder | Alkermes
strong launch trajectory established in with clear strategic focus in | Alkermes
lai for schizophrenia with dosing flexibility | Alkermes
lai for the treatment of dependence and alcohol dependence | Alkermes
offers long term revenue growth opportunity | Alkermes
advance receptor agonist | Alkermes
dysfunction well defined opportunity in narcolepsy and other sleep disorders | Alkermes
leveraging alkermes molecular design capabilities to target dysfunction | Alkermes
selective agonist showed dose dependent increased wakefulness and reduced cataplexy in preclinical models | Alkermes
selective receptor agonist promoted prolonged wakefulness in preclinical in studies | Alkermes
clinical development plan designed to rapidly advance program in | Alkermes
clinical development plan targeting clinical proof of concept data by year end | Alkermes
separate oncology business | Alkermes
post separation oncology pure play development stage oncology company stage | Alkermes
artistry durable responses observed | Alkermes
artistry development program | Alkermes
positioning alkermes business for future growth | Alkermes
post separation alkermes pure play commercial stage company | Alkermes
topline growth and diversification reflect evolving business | Alkermes
updated profitability targets reflect one year acceleration of previously provided targets | Alkermes
clear priorities to unlock value in | Alkermes
alkermes | Alkermes
See More
Alkermes
Investor Presentation Decks
Drug Manufacturers—Specialty & Generic Decks
Healthcare Decks
Related Content
Articles:
Barbarians at the Gate
Explore Topics
Oncology
Manufacturing
Monotherapy
Royalty
Solid tumor
Recent decks by Alkermes
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
See all presentations by Alkermes (22 decks)
Related decks
BioNTech
Results
March 2021
BioNTech
Results
May 2021
TScan Therapeutics
IPO
July 2021
Immatics
Investor Presentation
November 2023
BioNTech
Results
November 2021
Nuvectis Pharma
Investor Presentation
December 2023
BioAtla
Investor Presentation
January 2024
Fusion Pharmaceuticals
Investor Presentation
January 2024
Recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
BioNTech
Results
March 2021
BioNTech
Results
May 2021
TScan Therapeutics
IPO
July 2021
Immatics
Investor Presentation
November 2023
BioNTech
Results
November 2021
Nuvectis Pharma
Investor Presentation
December 2023
BioAtla
Investor Presentation
January 2024
Fusion Pharmaceuticals
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io